<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679298</url>
  </required_header>
  <id_info>
    <org_study_id>703/2020BO1</org_study_id>
    <nct_id>NCT04679298</nct_id>
  </id_info>
  <brief_title>Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Extended</brief_title>
  <acronym>POCT-DOAC ext</acronym>
  <official_title>Qualitative Coagulation Testing With the CoaguChek(R) Pro II Point-of-Care Test System and aPTT Test Cards in Patients Before and After First Intake of Direct Oral Anticoagulants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Diabetes Center North Rhine-Westphalia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' study aims to test the correlation between CoaguChek point-of-care aPTT&#xD;
      testing (Roche, Switzerland) and low plasma levels of all four currently EMA approved direct&#xD;
      oral anticoagulants (DOAC; apixaban, dabigatran, edoxaban, and rivaroxaban) and to determine&#xD;
      the diagnostic accuracy of POCT to rule out or detect relevant levels of DOAC in real-life&#xD;
      stroke patients. Relevant levels are defined as current treatment thresholds according to&#xD;
      international guidelines, i.e. 30 and 50 ng/mL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In emergency situations such as an acute stroke or emergency surgery, information on the&#xD;
      plasma concentration of DOAC in patients with suspected or known intake of DOAC plays a vital&#xD;
      role in making decisions in relation to the administration of i.v thrombolysis therapy-&#xD;
      ''Time is brain'' or to consider the administration of an antidote in acute hemorrhagic&#xD;
      stroke patients. Moreover, acute stroke patients presenting with aphasia are not in the&#xD;
      position to provide information on how regular and when last the anticoagulant was taken.&#xD;
&#xD;
      Although dabigatran for example has lab tests such as the diluted thrombin time (dTT) and the&#xD;
      ecarin clotting time (ECT) available, major challenges faced are due to the scarcity of these&#xD;
      tests in many hospitals. Also, just like many other lab tests, results could take up to 30-60&#xD;
      minutes (turn-around time due to transport and sample processing) making it inconvenient in&#xD;
      critical situations.&#xD;
&#xD;
      In our previous studies, we have been able to show a concentration-dependent effect of&#xD;
      Dabigatran on Hemochron® Signature POCT (Werfen, Barcelona, Spain) with all 4 test cards used&#xD;
      (PT, aPTT, ACT-LR und ACT+). Dabigatran however failed to show a concentration-dependent&#xD;
      effect when tested with the CoaguChek®XS Pro POCT device (Roche, Switzerland) together with&#xD;
      the then available prothrombin time (PT) test card. This finding could be attributed to the&#xD;
      known low response of dabigatran plasma levels on PT but rather a better response of&#xD;
      dabigatran plasma levels on aPTT.&#xD;
&#xD;
      Our study therefore aims to test CoaguChek® Pro II POCT device which is widely available in&#xD;
      Europe with the new aPTT test card on all 4 DOAC in order to assess a possible correlation&#xD;
      between the aPTT values and the DOAC plasma concentration detected by mass spectrometry, and&#xD;
      to evaluate its ability to rule out even very low but clinically relevant DOAC concentrations&#xD;
      (e.g., above the currently recommended 30 and 50 ng/mL treatment thresholds). In order to&#xD;
      avoid POCT results indicating no relevant DOAC concentrations despite DOAC concentrations&#xD;
      being actually elevated, our specificity target is predefined as &gt;95% for detection of&#xD;
      elevated DOAC concentrations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effect/Correlation of direct oral anticoagulants (DOAC) on aPTT CoaguChek® Pro II point-of-care testing (POCT) result</measure>
    <time_frame>24 hours</time_frame>
    <description>DOAC concentrations will be determined by ultra-performance liquid chromatography-tandem mass spectrometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of the CoaguChek® Pro II POCT to rule out or detect relevant DOAC levels</measure>
    <time_frame>24 hours</time_frame>
    <description>aPTT test card specificity and sensitivity do rule out or detect relevant DOAC plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect/Correlation of DOAC on calibrated DOAC-specific coagulation assays</measure>
    <time_frame>24 hours</time_frame>
    <description>Response of calibrated anti-thrombin/Xa activity assays to dabigatran/factor Xa inhibitors' plasma levels</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Anticoagulation With Direct Oral Anticoagulants</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Edoxaban</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive stroke patients, who were newly started on oral anticoagulation with apixaban,&#xD;
        edoxaban, dabigatran or rivaroxaban for secondary prevention of thromboembolic events&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Stroke patients, who were newly started on oral anticoagulation with apixaban,&#xD;
             edoxaban, dabigatran or rivaroxaban for secondary prevention of thromboembolic events&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vitamin K antagonists ≤ 14 days prior to study participation&#xD;
&#xD;
          -  Prior DOAC intake ≤ 72 hours&#xD;
&#xD;
          -  Low-molecular weight heparin ≤ 24 hours&#xD;
&#xD;
          -  Unfractionated heparin ≤ 12 hours&#xD;
&#xD;
          -  Heparinoids (e.g. Fondaparinux) ≤ 72 hours&#xD;
&#xD;
          -  Abnormal coagulation values at baseline (Quick &lt; 70% or activated thromboplastin time&#xD;
             (aPTT) &gt; 40sec.)&#xD;
&#xD;
          -  History of coagulopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sven Poli, MD MSc</last_name>
    <phone>+49(0)707129</phone>
    <phone_ext>83349</phone_ext>
    <email>sven.poli@uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joshua Mbroh, MD MSc</last_name>
    <phone>+49(0)707129</phone>
    <phone_ext>80418</phone_ext>
    <email>joshua.mbroh@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72070</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Poli, MD MSc</last_name>
      <phone>+49(0)707129</phone>
      <phone_ext>83349</phone_ext>
      <email>sven.poli@uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Joshua Mbroh, MD MSc</last_name>
      <phone>+49(0)707129</phone>
      <phone_ext>80418</phone_ext>
      <email>joshua.mbroh@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Ebner M, Birschmann I, Peter A, Härtig F, Spencer C, Kuhn J, Blumenstock G, Zuern CS, Ziemann U, Poli S. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions. Stroke. 2017 Sep;48(9):2457-2463. doi: 10.1161/STROKEAHA.117.017981. Epub 2017 Aug 3.</citation>
    <PMID>28775134</PMID>
  </reference>
  <reference>
    <citation>Ebner M, Birschmann I, Peter A, Spencer C, Härtig F, Kuhn J, Blumenstock G, Zuern CS, Ziemann U, Poli S. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Crit Care. 2017 Feb 15;21(1):32. doi: 10.1186/s13054-017-1619-z.</citation>
    <PMID>28196509</PMID>
  </reference>
  <reference>
    <citation>Ebner M, Peter A, Spencer C, Härtig F, Birschmann I, Kuhn J, Wolf M, Winter N, Russo F, Zuern CS, Blumenstock G, Ziemann U, Poli S. Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants. Stroke. 2015 Oct;46(10):2741-7. doi: 10.1161/STROKEAHA.115.010148. Epub 2015 Aug 13.</citation>
    <PMID>26272385</PMID>
  </reference>
  <reference>
    <citation>Härtig F, Birschmann I, Peter A, Hörber S, Ebner M, Sonnleitner M, Spencer C, Bombach P, Stefanou MI, Kuhn J, Mengel A, Ziemann U, Poli S. Point-of-care testing of coagulation in patients treated with edoxaban. J Thromb Thrombolysis. 2020 Oct;50(3):632-639. doi: 10.1007/s11239-020-02143-2.</citation>
    <PMID>32436010</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Direct oral anticoagulants</keyword>
  <keyword>Acute stroke</keyword>
  <keyword>Point-of-care testing</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

